Association Between Circulating Levels of Adiponectin and Indices of Bone Mass and Bone Metabolism in Middle-aged Post-menopausal Women

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2011 May 25

PMID 21606670

Citations 8

Authors

R Tenta

M D Kontogianni

N Yiannakouris

Affiliations

Soon will be listed here.

Abstract

Background: Adiponectin, a fat derived cytokine, is a potential independent contributor to bone mineral density (BMD); however, its action on bone metabolism in humans is still unclear.

Aim: The aim of this study was to investigate the relationship of adiponectin with bone mass indices and bone metabolic markers in middle-aged post-menopausal women without diabetes.

Subjects And Methods: A random sample consisted of 81 post-menopausal women (age range 45-61 yr, osteopenic/osteoporotic no.=43) was studied. Lumbar-spine BMD (BMD(L2-L4)) and total-body bone mineral content (TBBMC) were measured with dual X-ray absorptiometry. Plasma levels of total and high-molecular weight (HMW) adiponectin, osteoprotegerin (OPG), soluble receptor activator of nuclear factor-κB ligand (sRANKL) and IGF-I were determined.

Results: No association was observed between total or HMW adiponectin and BMD(L2-L4) or TBBMC. On the contrary, adiponectin levels were positively associated with OPG levels (partial r=0.276, p=0.015) and negatively with IGF-I (partial r=-0.438, p<0.001), in multiple regression models after adjustment for potential confounders. HMW adiponectin showed a negative association with IGF-I (partial r=-0.266, p=0.049) in the multiple regression models but not with OPG, TBBMC or BMD(L2-L4).

Conclusions: Although we failed to show statistically significant association between circulating adiponectin levels and indices of bone mass in women during the postmenopausal period, we showed significant associations with OPG and IGF-I levels, suggesting an anabolic role of adiponectin, which may contribute in the understanding of the interplay between adipose tissue-derived hormones and bone metabolism.

Citing Articles

Effect of adipokine and ghrelin levels on BMD and fracture risk: an updated systematic review and meta-analysis.

Lee S, Kim J, Jeon Y, Lee J, Kim K, Hwang S Front Endocrinol (Lausanne). 2023; 14:1044039.

PMID: 37181034 PMC: 10171108. DOI: 10.3389/fendo.2023.1044039.

ADIPONECTIN AS A POTENTIAL BIOMARKER OF LOW BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN WITH METABOLIC SYNDROME.

Stojanovic S, Arsenijevic N, Djukic A, Djukic S, Zivancevic Simonovic S, Jovanovic M Acta Endocrinol (Buchar). 2019; 14(2):201-207.

PMID: 31149258 PMC: 6516524. DOI: 10.4183/aeb.2018.201.

The Unique Metabolic Characteristics of Bone Marrow Adipose Tissue.

Li Y, Meng Y, Yu X Front Endocrinol (Lausanne). 2019; 10:69.

PMID: 30800100 PMC: 6375842. DOI: 10.3389/fendo.2019.00069.

Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis.

Filip R, Radzki R, Bienko M Clin Interv Aging. 2018; 13:1879-1891.

PMID: 30323574 PMC: 6174895. DOI: 10.2147/CIA.S170533.

Association between omentin-1, adiponectin and bone health under consideration of osteoprotegerin as possible mediator.

Menzel J, Di Giuseppe R, Biemann R, Aleksandrova K, Kuxhaus O, Wittenbecher C J Endocrinol Invest. 2016; 39(11):1347-1355.

PMID: 27614458 PMC: 5069301. DOI: 10.1007/s40618-016-0544-3.

References

Basurto L, Galvan R, Cordova N, Saucedo R, Vargas C, Campos S . Adiponectin is associated with low bone mineral density in elderly men. Eur J Endocrinol. 2008; 160(2):289-93. DOI: 10.1530/EJE-08-0569. View

Wittrant Y, Theoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D . RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta. 2004; 1704(2):49-57. DOI: 10.1016/j.bbcan.2004.05.002. View

Ozkurt B, Ozkurt Z, Altay M, Aktekin C, Caglayan O, Tabak Y . The relationship between serum adiponectin level and anthropometry, bone mass, osteoporotic fracture risk in postmenopausal women. Eklem Hastalik Cerrahisi. 2009; 20(2):78-84. View

Michaelsson K, Lind L, Frystyk J, Flyvbjerg A, Gedeborg R, Berne C . Serum adiponectin in elderly men does not correlate with fracture risk. J Clin Endocrinol Metab. 2008; 93(10):4041-7. DOI: 10.1210/jc.2008-0617. View

Kanazawa I, Yamaguchi T, Sugimoto T . Baseline serum total adiponectin level is positively associated with changes in bone mineral density after 1-year treatment of type 2 diabetes mellitus. Metabolism. 2010; 59(9):1252-6. DOI: 10.1016/j.metabol.2009.11.017. View

Agbaht K, Gurlek A, Karakaya J, Bayraktar M . Circulating adiponectin represents a biomarker of the association between adiposity and bone mineral density. Endocrine. 2009; 35(3):371-9. DOI: 10.1007/s12020-009-9158-2. View

Jurimae J, Jurimae T, Leppik A, Kums T . The influence of ghrelin, adiponectin, and leptin on bone mineral density in healthy postmenopausal women. J Bone Miner Metab. 2008; 26(6):618-23. DOI: 10.1007/s00774-008-0861-5. View

Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S . Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem. 2003; 278(41):40352-63. DOI: 10.1074/jbc.M300365200. View

Berner H, Lyngstadaas S, Spahr A, Monjo M, Thommesen L, Drevon C . Adiponectin and its receptors are expressed in bone-forming cells. Bone. 2004; 35(4):842-9. DOI: 10.1016/j.bone.2004.06.008. View

10.

Oshima K, Nampei A, Matsuda M, Iwaki M, Fukuhara A, Hashimoto J . Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun. 2005; 331(2):520-6. DOI: 10.1016/j.bbrc.2005.03.210. View

11.

Luo X, Guo L, Xie H, Yuan L, Wu X, Zhou H . Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res. 2006; 21(10):1648-56. DOI: 10.1359/jbmr.060707. View

12.

Gannage-Yared M, Yaghi C, Habre B, Khalife S, Noun R, Germanos-Haddad M . Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. Eur J Endocrinol. 2008; 158(3):353-9. DOI: 10.1530/EJE-07-0797. View

13.

Rubin J, Ackert-Bicknell C, Zhu L, Fan X, Murphy T, Nanes M . IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. J Clin Endocrinol Metab. 2002; 87(9):4273-9. DOI: 10.1210/jc.2002-020656. View

14.

Ziemke F, Mantzoros C . Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr. 2009; 91(1):258S-261S. PMC: 2793112. DOI: 10.3945/ajcn.2009.28449C. View

15.

Yakar S, Rosen C, Beamer W, Ackert-Bicknell C, Wu Y, Liu J . Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 2002; 110(6):771-81. PMC: 151128. DOI: 10.1172/JCI15463. View

16.

. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843:1-129. View

17.

Rubin C, Lanyon L . Regulation of bone mass by mechanical strain magnitude. Calcif Tissue Int. 1985; 37(4):411-7. DOI: 10.1007/BF02553711. View

18.

Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H . Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care. 2006; 29(6):1357-62. DOI: 10.2337/dc05-1801. View

19.

Peng X, Xie H, Zhao Q, Wu X, Sun Z, Liao E . Relationships between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in Chinese men. Clin Chim Acta. 2007; 387(1-2):31-5. DOI: 10.1016/j.cca.2007.08.012. View

20.

Yannakoulia M, Yiannakouris N, Melistas L, Kontogianni M, Malagaris I, Mantzoros C . A dietary pattern characterized by high consumption of whole-grain cereals and low-fat dairy products and low consumption of refined cereals is positively associated with plasma adiponectin levels in healthy women. Metabolism. 2008; 57(6):824-30. DOI: 10.1016/j.metabol.2008.01.027. View